Also known as: Vyloy, VYLOY
AstraZeneca will report pivotal first-half data on sonesitatug vedotin in Claudin18.2 gastric cancer. The phase 3 Clarity-Gastric01 study is enrolling patients with ≥25% expression.
VYLOY (zolbetuximab-clzb) remains the only approved CLDN18.2-targeted therapy for first-line HER2-negative gastric or gastroesophageal junction adenocarcinoma with CLDN18.2-positive tumors. The pipeline is focused on next-generation antibodies, ADCs, CAR-T, NK-cell and bispecific approaches aiming to build on zolbetuximab benchmark data.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07484113 |
IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD |
NOT_YET_RECRUITING | PHASE1 |
| NCT07286214 |
Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica |
RECRUITING | PHASE4 |
| NCT07154290 |
A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) |
RECRUITING | PHASE2 |
| NCT06787612 |
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT05535738 |
Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
ACTIVE_NOT_RECRUITING | PHASE2/PHASE3 |
| NCT03564340 |
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers |
RECRUITING | PHASE1/PHASE2 |
| NCT03414502 |
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response |
RECRUITING | PHASE3 |
